SAL003 140 mg
Sponsors
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Conditions
HyperlipidemiasHyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia
CompletedNCT07253584
Start: 2023-12-19End: 2025-06-30Updated: 2025-11-28
A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia
CompletedNCT07295418
Start: 2023-10-23End: 2025-05-08Updated: 2025-12-19